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Background. Sentinel lymph node biopsy (SLNB) for thick cutaneous melanoma is supported by national guidelines. We report
on factors associated with the use and underuse of SLNB for thick primary cutaneous melanoma. Methods. e Surveillance,
Epidemiology, and End Results database was queried for patients who underwent surgery for thick primary cutaneous melanoma
from 2004 to 2008. We used multivariate logistic regression models to predict use of SLNB. Results. Among 1,981 patients, 833
(41.8%) did not undergo SLNB. Patients with primary melanomas of the arm (OR 2.07, CI 1.56–2.75; 𝑃𝑃 𝑃 𝑃𝑃𝑃𝑃𝑃), leg (OR 2.40, CI
1.70–3.40; 𝑃𝑃 𝑃 𝑃𝑃𝑃𝑃𝑃), and trunk (OR 1.82, CI 1.38–2.40; 𝑃𝑃 𝑃 𝑃𝑃𝑃𝑃𝑃) had an increased likelihood of receiving a SLNB, as did those
with desmoplastic histology (OR 1.47, CI 1.11–1.96;𝑃𝑃 𝑃 𝑃𝑃𝑃𝑃𝑃). A decreased likelihood of receiving SLNBwas noted for advancing
age ≥ 60 years (age 60 to 69: OR 0.58, CI 0.33–0.99, 𝑃𝑃 𝑃 𝑃𝑃𝑃𝑃𝑃; age 70 to 79: OR 0.32, CI 0.19–0.54, 𝑃𝑃 𝑃 𝑃𝑃𝑃𝑃𝑃; age 80 or more: OR
0.10, CI 0.06–0.16, 𝑃𝑃 𝑃 𝑃𝑃𝑃𝑃𝑃) and unknown race/ethnicity (OR 0.21, CI 0.07–0.62; 𝑃𝑃 𝑃 𝑃𝑃𝑃𝑃𝑃). Conclusions. In particular, elderly
patients are less likely to receive SLNB. Further research is needed to assess whether use of SLNB in this population is detrimental
or bene�cial.
1. Introduction
Lymphatic mapping and sentinel lymph node biopsy (SLNB)
was developed by Morton et al. as an alternative to elective
lymph node dissection for patients with intermediate thick-
ness melanoma [1]. However, information from institutional
studies and post hoc analyses from randomized clinical trials
indicate that SLNBprovides accurate and important prognos-
tic information, even among patients with thick melanoma
[2–11]. Current guidelines from the National Comprehen-
sive Cancer Network (NCCN) advocate the SLNB for all
melanomas >1mm in thickness [12]. Such guidelines have
been in place since 1998 [13].
e use of SLNB for thick cutaneousmelanomas has nev-
ertheless remained controversial due to the nihilistic belief
that thick melanomas are associated with an unacceptably
high likelihood of distant metastatic disease [14]. Given that
only half of all patients with thick primarymelanomas will be
alive 10 years aer their diagnosis, [2] somephysicians believe
that such patients are unlikely to bene�t from SLNB because
their outcome will be dictated by their occult metastasis
and not the presence or absence of sentinel lymph node
metastasis.
To date, little data have been acquired regarding use
of SLNB for thick melanomas, and the factors that may
contribute to its use are largely unknown. Our goals were
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to assess the prevalence of SLNB use for thick primary
cutaneous melanoma and to identify clinical and pathologic
factors associatedwith its use or underuse utilizing a national,
population-based database.
2. Methods
We used the Surveillance, Epidemiology, and End Results
(SEER) database to identify patients diagnosed with thick
(known Breslow depth > 4.00mm) primary cutaneous
melanoma treated surgically from 2004 to 2008. ese years
were selected because they were subsequent to reports in the
surgical and oncology literature supportive of SLNB for thick
primary cutaneous melanoma and guidelines established in
1998 [13]. e registries, attributes, and limitations of the
SEER database have been reported previously [15]. Because
SEER data are de identi�ed, this research was exempt from
Institutional Review Board approval.
We excluded patients with mucosal melanoma, those
without a biopsy-proven diagnosis, those diagnosed at auto-
psy, patients whose lymph node evaluation was unknown,
or other than SLNB “yes” or SLNB “no”. Patients who had a
lymph node evaluation other than SLNB were also excluded,
as it was assumed that these patients likely had clinically
evident, palpable disease and underwent formal complete
lymphadenectomy.
To assess the proportion of patients with thick primary
melanomas undergoing SLNB over time, we tabulated the
number of SLNB procedures performed relative to the total
number of cases of thick primary cutaneous melanoma per
year.
We used multivariate logistic regression to predict use of
SLNB. Covariates examined in the model included patient
age (ages 1 to 39; 40 to 49; 50 to 59; 60 to 69; 70 to 79;
80 or more), sex, race/ethnicity (Asian, black, Hispanic, and
white), Breslow depth (continuous variable per 0.01mm),
tumor histology (acral lentiginous, amelanotic, desmoplas-
tic, epidermoid, lentigo maligna, nevus associated, nodular,
regressing, and super�cial spreading), tumor location (arm,
head/neck, leg, trunk, and overlapping), and ulceration status
(yes, no, and unknown). e likelihood of undergoing SLNB
was reported as odds ratios (OR) with 95% con�dence
intervals (CI). Signi�cance was set at 𝑃𝑃 𝑃 𝑃𝑃𝑃𝑃. All statistical
analyses were performed using STATA 11 (College Station,
TX).
3. Results
Among 1,981 patients with thick primary cutaneous mela-
noma, 833 (41.8%) did not undergo SLNB. e majority
of patients were white (91.7%), male (63.6%), and elderly,
with approximately 70% of patients being age 60 or older.
e mean Breslow thickness of the primary cutaneous
melanomas in this group of patients with thick melanomas
was 6.55mm. Tumor ulceration was noted in 54.7% of
cases. Melanomas were mostly of nodular (52.7%), desmo-
plastic (19.3%), and super�cial spreading (14.9%) histology.
Head/neck, arm, and truncal tumor sites were almost equally
represented (28.9%, 28.2%, and 25.3%, resp.). We looked at
the proportion of patients receiving SLNB for their thick
cutaneous melanoma by year of diagnosis. ere was a
general trend towards increasing utilization of SLNB, with
50.8% of patients having the procedure in 2004, 58% in 2005,
56.4% in 2006, 63.5% in 2007, and 61.1% having it in 2008.
Patient and tumor characteristics of the study population
according to whether or not a SLNB was performed are
included in Table 1. When divided into those that received a
SLNB and those that did not receive a SLNB, the two groups
were found to signi�cantly di�er with respect to patient
age, mean Breslow tumor depth, and tumor location. ose
in the no SLNB group had a greater proportion of elderly
patients (80 years or older), thinnermelanomas, and a greater
proportion of head/neck tumor sites than those in the SLNB
group.
Results of the multivariate logistic regression analysis are
presented in Table 2. Factors associated with a decreased
likelihood of receiving a SLNB included age 60 to 69 (OR0.58,
CI 0.33–0.99; 𝑃𝑃 𝑃 𝑃𝑃𝑃𝑃𝑃), 70 to 79 (OR 0.32, CI 0.19–0.54;
𝑃𝑃 𝑃 𝑃𝑃𝑃𝑃𝑃), 80 years or older (OR 0.10, CI 0.06-0.16, 𝑃𝑃 𝑃
𝑃𝑃𝑃𝑃𝑃), and unknown race/ethnicity (OR 0.21, CI 0.07–0.62,
𝑃𝑃 𝑃 𝑃𝑃𝑃𝑃𝑃). Factors associated with an increased likelihood
of receiving a SLNB included primary melanomas of the
arm (OR 2.07, CI 1.56–2.75; 𝑃𝑃 𝑃 𝑃𝑃𝑃𝑃𝑃), leg (OR 2.40, CI
1.70–3.40; 𝑃𝑃 𝑃 𝑃𝑃𝑃𝑃𝑃), and trunk (OR 1.82, CI 1.38–2.40;
𝑃𝑃 𝑃 𝑃𝑃𝑃𝑃𝑃), as well as desmoplastic histology (OR 1.47, CI
1.11–1.96; 𝑃𝑃 𝑃 𝑃𝑃𝑃𝑃𝑃).
4. Discussion
Despite the fact that SLNB for lymph node staging of
thick primary cutaneous melanomas has been advocated
by national guidelines since 1998 [13] and supported by
retrospective and prospective institutional data [2–11], its
use in this setting is frequently cited as controversial. While
we support the use of SLNB as a staging tool for patients
with thick primary cutaneousmelanoma, we understand that
some surgeons have a bias against its use in this setting.
Our goals were to identify the proportion of patients with
thick melanomas undergoing SLNB and to assess patient
and tumor-related factors that may contribute to the use or
underuse of SLNB.
In our current study of 1,981 patients with thick pri-
mary cutaneous melanoma, 41.8% did not have a SLNB.
is is higher than the 19.5% underuse rate reported by
Meguerditchian et al. Most in an institutional review of 113
similar patients [16]. ere are several possible explanations
for this discrepancy. Among them is an important limitation
of the SEER database. SEER does not provide information
on individual patient comorbidities that may in�uence the
recommendation to perform a SLNB. For example, a surgeon
may be more likely to perform a SLNB on a healthy 80-year-
old man than a similarly aged man with diabetes, congestive
heart failure, and exercise limiting chronic obstructive pul-
monary disease, but SEER cannot shed light on this aspect of
the treatment decision-making process.
We found that the likelihood of receiving a SLNB was
inversely proportional with age, with patients aged 60 years
and older having a decreased likelihood of undergoing
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T 1: Patient and tumor characteristics of 1,991 patients with
thick primary cutaneous melanoma according to whether or not
they received a sentinel lymph node biopsy (SLNB).
Variable
SLNB,
N = 1,158 (%)
No SLNB,
N = 833 (%) P value
Age, years
1 to 39 97 (8.4) 21 (2.5)
<0.001
40 to 49 135 (11.7) 43 (5.2)
50 to 59 239 (20.6) 65 (7.8)
60 to 69 243 (21) 97 (11.6)
70 to 79 268 (23.1) 192 (23.1)
80 or more 176 (15.2) 415 (49.8)
Sex
Female 416 (35.9) 525 (63) =0.631
Male 742 (64.1) 308 (37)
Race/ethnicity
Asian 22 (1.9) 8 (1)
=0.062
Black 13 (1.1) 14 (1.7)
Hispanic 55 (4.8) 30 (3.6)
Native American 6 (0.5) 1 (0.1)
Unknown 6 (0.5) 10 (1.2)
White 1,056 (91.2) 770 (92.4)
Mean Breslow depth
(mm) 6.83 6.35 <0.001
Tumor histology
Acral lentiginous 58 (5) 26 (3.1)
=0.053
Amelanotic 33 (2.9) 19 (2.3)
Desmoplastic 225 (19.4) 160 (19.2)
Epidermoid 28 (2.4) 16 (1.9)
Lentigo maligna 16 (1.4) 23 (2.8)
Nevus associated 7 (0.6) 4 (0.5)
Nodular 606 (52.3) 463 (55.6)
Regressing 9 (0.8) 1 (0.1)
Super�cial Spreading 176 (15.2) 121 (14.5)
Tumor location
Arm 301 (26) 202 (24.3)
<0.001
Head/neck 261 (22.5) 315 (37.8)
Leg 226 (19.5) 114 (13.7)
Trunk 368 (31.8) 194 (23.3)
Overlapping/other 2 (0.2) 8 (1)
Tumor ulceration
No 501 (43.3) 356 (42.7)
=0.857Yes 632 (54.6) 456 (54.7)
Unknown 25 (2.2) 21 (2.5)
a SLNB. �is �nding is consistent with our previously
reported �nding that elderly patients are less likely to receive
SLNB for intermediate thickness melanoma [17]. Older
patients are more likely than their younger counterparts
to have comorbidities that may in�uence the decision of
T 2: Multivariate logistic regression model of the entire cohort
(2004–2008) predicting use of sentinel lymph node biopsy (SLNB).
Variable Odds Ratio (95% CI) 𝑃𝑃 value
Age, years
1 to 39 Referent Referent
40 to 49 0.74 (0.41–1.35) =0.325
50 to 59 0.84 (0.48–1.47) =0.547
60 to 69 0.58 (0.33–0.99) =0.047
70 to 79 0.32 (0.19–0.54) <0.001
80 or more 0.10 (0.06–0.16) <0.001
Sex
Male Referent Referent
Female 0.93 (0.75–1.16) =0.532
Race/ethnicity
White Referent Referent
Asian 1.54 (0.61–3.91) =0.359
Black 0.54 (0.23–1.27) =0.158
Hispanic 0.85 (0.51–1.41) =0.523
Native American 4.62 (0.45–47.63) =0.198
Unknown 0.21 (0.07–0.62) =0.005
Mean Breslow depth
(per 1/100mm) 0.99 (0.99–1.00) <0.001
Tumor histology
Nodular Referent Referent
Acral lentiginous 1.08 (0.61–1.92) =0.786
Amelanotic 1.21 (0.64–2.30) =0.555
Desmoplastic 1.47 (1.11–1.96) =0.008
Epidermoid 1.36 (0.67–2.76) =0.388
Lentigo maligna 0.93 (0.45–1.91) =0.850
Nevus associated 0.91 (0.24–3.45) =0.887
Regressing 4.83 (0.58–40.47) =0.147
Super�cial Spreading 0.91 (0.68–1.23) =0.549
Tumor location
Head/neck Referent Referent
Arm 2.07 (1.56–2.75) <0.001
Leg 2.40 (1.70–3.40) <0.001
Trunk 1.82 (1.38–2.40) <0.001
Overlapping/other 0.23 (0.04–1.22) =0.084
Tumor ulceration
Yes Referent Referent
No 0.88 (0.71–1.09) =0.234
Unknown 0.63 (0.33–1.22) =0.172
whether or not to o�er SLNB. Signi�cant comorbidities,
when added to the risk of distant metastasis and subsequent
mortality from a thick primary cutaneous melanoma, may be
perceived to overshadow any potential bene�t obtained from
the SLNB in terms of accurate staging and early complete
lymphadenectomy in the case of node positive disease. Poorer
overall survival among elderly patients is to be expected.
However, Göpper et al. found that, eventhough increasing
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age was associated with decreased overall survival, this effect
was dominated by the prognostic importance of the sentinel
lymph node status [18]. Among the largest single institution
series was reported by Gajdos et al. [19]. ey examined 227
patients with thick (T4) melanoma who underwent SLNB
from 1997 to 2007 and similarly found that increasing age
negatively in�uenced overall survival. Again, however, the
in�uence of advancing age was dominated by the status of the
sentinel lymph node.When patients were further categorized
into sentinel lymph node negative and sentinel lymph node
positive groups, increasing age was found to be a prognostic
factor only for the sentinel lymph node negative group.
Together, these �ndings indicate that, even as age increases,
the sentinel node status may still provide valuable prognostic
information.
In our study, we noted that patients of unknown
race/ethnicity were signi�cantly less likely to undergo SLNB.
We have no de�nitive explanation for this �nding. Our
patient population was > 90% white, with very few (𝑁𝑁 𝑁 𝑁𝑁)
being of unknown race/ethnicity. It is most likely that this
�nding is unreliable for this reason.
Increasing Breslow thickness negatively in�uenced the
likelihood of receiving a SLNB in our study. Our multivariate
model assessed the likelihood of receiving a SLNB for each
0.01mm increase in Breslow thickness. For every 0.01mm
increase in Breslow depth, there was a 0.5% decrease in
the odds of receiving a SLNB. is translates into a 14.5%
decrease in the odds of receiving a SLNB for every 1mm
increase in Breslow thickness. is is likely explained by
a growing sense of nihilism about the likelihood of occult
distant metastatic disease as the primary tumor increases in
thickness. It is somewhat unclear if the nihilism is warranted,
however. Carlson et al. studied 114 patients with thick
melanoma who underwent SLNB and found that the thickest
tumors (>6mm) were not associated with increased risks of
overall or relapse-free survival [20]. Using tumor thickness
as a continuous variable in a multivariate model, Gutzmer
et al. failed to identify any in�uence of increasing melanoma
thickness on overall survival [6]. Similarly, Gershenwald et
al. noted no in�uence of increasing tumor thickness on either
disease-free or overall survival among 131 patients with thick
melanomas undergoing SLNB [5]. Both Ferrone et al. [4]
and Jacobs et al. [7] documented a higher risk of disease
recurrence with increasing tumor thickness, but they did not
examine any in�uence on overall survival.
We found that patients with thick desmoplastic mela-
nomas were less likely to undergo SLNB. It is possible that
SLNB was less commonly offered in these patients because
desmoplastic melanomas have been shown to have lower
rates of sentinel lymph node metastasis [21]. Addition-
ally, desmoplastic melanomas are more common on the
head/neck, and these areas may be more challenging for
lymphatic mapping and SLNB may therefore be deferred in
favor of clinical observation. Indeed, in our analysis, relative
to head/neck primary sites, patients with melanomas of the
trunk and extremities were approximately twice as likely to
undergo SLNB.
Although the presence of tumor ulceration plays a signif-
icant role in several models assessing the prognostic utility
of SLNB in patients with thick melanoma, [4, 5, 7, 20]
ulceration did not seem to in�uence the use of SLNB in
our patient cohort. is could re�ect a relationship between
tumor ulceration and Breslow thickness. As previously stated,
we found that increasingly thick melanomas were less likely
to undergo SLNB.Due to tumor ulceration, the depth of some
melanomas may be underestimated. With these “thinner”
melanomas being perceived as “less risky” for occult metasta-
sis, surgeonsmay opt to pursue SLNBmore readily. However,
Bilimoria et al. examined the records of 8,525 stage IB and
II melanoma patients in the National Cancer Data Base and
found that those with no tumor ulceration were less likely to
undergo SLNB [22].
Our data may be subject to selection bias, since we only
included patients for whom data was complete regarding
whether or not SLNB was performed. Such a decision
provided us with a more homogeneous population and
allowed us to exclude patients that underwent a com-
plete lymphadenectomy, likely because of clinically palpable
nodal disease. Nevertheless, we may have excluded patients
that would have otherwise altered our measured outcomes.
Finally, SEER does not provide information on patient-
level socioeconomic status such as monthly/yearly income
or surrogates of socioeconomic status like education level or
insurance status. Such factorsmay in�uence access to optimal
cancer care and may partially explain the relatively high
percentage of patients not undergoing SLNB in our study.
SLNB for patients with thick primary cutaneous mela-
noma should no longer be considered controversial. Despite
this, a signi�cant proportion of patients do not undergo
lymph node staging with SLNB. We have demonstrated that
patients age 60 years and older are less likely to receive SLNB.
To date, data do not suggest that limiting SLNB in the elderly
is appropriate. Further research to assesswhether use of SLNB
in older patients is detrimental or bene�cial is needed.
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